{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for icosapent root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT03486899: Phase 2 Interventional Completed Liver Fibrosis
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04171986: Not Applicable Interventional Unknown status Small Cell Lung Cancer
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00936403: Phase 2 Interventional Completed Growth Hormone Disorder
(2009)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
FERTIRELIN is an analog of luteinizing hormone releasing factor. The drug has been used since 1981 in Japan to treat various types of reproductive failure in cattle.
Status:
US Previously Marketed
Source:
MYOSCINT by CENTOCOR INC
(1996)
Source URL:
First approved in 1996
Source:
MYOSCINT by CENTOCOR INC
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
NUCLEIC ACID
Status:
Investigational
Source:
INN:gatuzosiran [INN]
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Class:
NUCLEIC ACID
